Corporate calendar for Cellectar Biosciences, Inc. (CLRB): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Stock Splits
| Date | Ratio |
|---|---|
| 2025-06-23 | 1:30 |
| 2022-07-21 | 1:10 |
| 2018-07-16 | 1:10 |
| 2016-03-06 | 1:10 |
| 2014-06-15 | 1:20 |
| 2011-04-10 | 1:153 |
Price
| Price | $2.35 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Related companies: AEON · BOLT · CING · EVGN · IMNN · LYRA · MBIO
Explore sector: Healthcare · Biotechnology
More sections of CLRB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks